BioCryst Pharmaceuticals Inc. shares (BCRX) surged more than 5% in premarket trade, after the company said it received a positive opinion on European orphan drug designation for its treatment for hereditary angioedema.
By Jeff Reeves, MarketWatch
For the most part, they're downplaying the company's biggest strengths
Google Inc. has become quite the dog since September, with the shares of the Internet search company slumping about 15%.
The biggest factor driving down the stock is the fallout from disappointing third-quarter results released in October.
By Jeffry Bartash, MarketWatch
Cheaper gas spurs 0.9% decline, but most retailers fare poorly
WASHINGTON (MarketWatch) -- Retail sales in the U.S. sank in December largely because consumers spent a lot less to fill up at the gas station, but most stores posted weak results during the busiest month of the shopping season, government data show.
Sign-up for - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Vivint Solar, Inc. and Lead Plaintiff Deadline of January 20, 2015 -- VSLR investment picks
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “ Company ”) confirms that, as of the close of
business on January 13, 2015, the Company’s issued share capital,
excluding treasury shares, consisted of 454,294,351 ordinary shares, par
value US$0.20 per share (the “ Ordinary Shares ”). The
International Securities Identification Number (ISIN) of the Ordinary
Shares is IE00B68SQD29.
Sign-up for - SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Cobalt International Energy, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015 - CIE investment picks
To help protect against potentially unsafe dental products entering the
marketplace, Patterson Companies, Inc. (Nasdaq: PDCO )
today announced that it is formalizing its efforts to promote supply
chain integrity for its dental customers.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.